An advocacy group is suing the Trump administration for failing to disclose details of a settlement with Gilead over patent ...

Results from early-stage trial show that 80% of participants who received one of two HIV vaccine candidates produced antibodies against viral proteins.

Scientific breakthroughs take center stage at the International AIDS Society Conference as global HIV funding and political support erode.

With Black women and straight men increasingly at risk, Gilead’s Yeztugo may finally offer a discreet, stigma-free way to ...

Scientists used a mRNA-based vaccine to reliably trigger antibodies that block HIV infection in people and monkeys ...

We may be a step closer to a highly effective mRNA vaccine against HIV, but tests so far reveal that the approach can cause ...

This story first appeared in the UNAIDS Global AIDS Update 2025 report.

Healio received an APEX award for a 2024 report on the cloudy future of HIV vaccine research in the age of long-acting ...

Conference on HIV Science on July 17 in Kigali, one message echoed with urgency across Africa—and especially in Kenya: the global HIV response is at a turning point. IAS 2025 was not just a conference ...

I could only feel shocked at first, like the air was knocked out of my body. My first thought was: My life is over. This is ...